Możliwość odstawienia nilotynibu u chorej na przewlekłą białaczkę szpikową w fazie głębokiej odpowiedzi molekularnej

Abstract

The advent of tyrosine kinase inhibitors (TKI) into the management of patients with chronic myelogenous leukemia (CML) has profoundly improved prognosis. In recent years, a numer of studies have been conducted to demonstrate the possibility and safety of TKI cessation in well responding patients. Strict criteria for when to stop TKI therapy in clinical practice are not easily defined. Despite many doubts, it seems that achieving treatment-free remission may become a standard part of CML treatment.